Press release
Tardive Dyskinesia (TD) Market Poised for Growth Amid Rising Treatment Adoption and Awareness
Tardive Dyskinesia (TD) Market
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/72077
1. Keyword Definition - Tardive Dyskinesia (TD)
Tardive Dyskinesia (TD) is a serious neurological movement disorder characterized by involuntary, repetitive movements - often affecting the face, limbs, or trunk. TD typically arises as a side-effect of long-term use of certain antipsychotic or neuroleptic medications. These involuntary movements can significantly impair daily functioning, quality of life, and may be persistent or worsen over time if not properly treated. Given growing use of antipsychotics globally, TD remains a critical unmet medical need in movement disorders and neuropsychiatric care.
2. Key Players in the TD Market
Major global pharmaceutical and biotech companies with active presence or interest in TD treatment or related movement-disorder therapies include:
• Roche (Genentech)
• Novartis AG
• Pfizer Inc.
• Teva Pharmaceutical Industries
• Lundbeck A/S
• Allergan (now part of AbbVie Inc.)
• Sunovion Pharmaceuticals
• Neurocrine Biosciences
• Takeda Pharmaceutical Company
• Merck & Co.
In addition to drug manufacturers, specialized neurology and psychiatry clinics, as well as care-management centers for movement disorders, contribute to the broader TD care ecosystem.
3. Key Events in Recent Years
• Improved clinical recognition and diagnostic criteria for Tardive Dyskinesia, leading to higher reported incidence
• Increased global use and broader availability of antipsychotic medications - raising the potential patient pool for TD
• Growing development and regulatory approval of novel therapies targeting movement disorders and TD symptoms
• Expansion of mental-health and neuro-care facilities worldwide, especially in emerging markets, improving patient access to TD diagnosis and treatment
• Rising advocacy and awareness programs for neuropsychiatric side-effects, driving demand for safer antipsychotic use and TD management
These shifts have expanded both the diagnosed base and potential treatment adoption for TD globally.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/72077/tardive-dyskinesia-market
4. Market Growth Rate (CAGR & Forecast)
According to current market analysis, the global Tardive Dyskinesia (TD) market was valued at approximately USD 1.3 billion in 2024. Over the next decade, it is projected to grow to around USD 2.4 billion by 2034, reflecting a compound annual growth rate (CAGR) of about 6.8%.
This projected growth is driven by increasing diagnosis rates, broader patient awareness, enhanced access to neurological care, and introduction of novel therapeutic and supportive-care options.
5. Market Segments and Their Growth Analysis
By Treatment Type:
• Novel pharmacologic therapies (disease-modifying or symptom-targeting)
• Supportive care and symptomatic treatments (e.g. muscle relaxants, physical therapy)
• Psychosocial and rehabilitation services
By End-User / Care Setting:
• Neurology and psychiatry hospitals/clinics
• Outpatient care centers and rehabilitation facilities
• Long-term care and psychiatric care facilities
• Home-care and outpatient supportive care
By Region:
• North America currently leads due to well-established mental-health care infrastructure and high antipsychotic use
• Europe maintains steady market share with mature healthcare systems
• Asia-Pacific is expected to show fastest growth - driven by rising mental-health awareness, increasing antipsychotic prescriptions, and expanding access to neurological care
By Patient Demographics:
• Long-term psychiatric patients previously treated with antipsychotics
• Older adults - who may be at elevated risk of TD
• New-onset TD patients following antipsychotic therapy
Get Your Exclusive Offer with up to 10% Discount
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72077
6. Key Market Drivers
• Rising global prevalence of neuropsychiatric disorders and increased use of antipsychotics
• Growing recognition and diagnosis of TD as a distinct clinical condition
• Development of newer, safer therapies and improved treatment approaches for movement disorders
• Expansion of mental-health and neurology care infrastructure worldwide
• Increased patient and clinician awareness of TD and its serious quality-of-life impacts
• Rising demand for long-term supportive and symptomatic care for TD patients
Still, challenges such as stigma associated with neuropsychiatric disorders, limited access to specialized care in some regions, and treatment cost may influence adoption.
7. Conclusion
The Tardive Dyskinesia (TD) market stands at the cusp of a growth wave, with increasing global demand for diagnosis, treatment, and long-term care. From an estimated USD 1.3 billion in 2024, the market is projected to reach around USD 2.4 billion by 2034, growing at a CAGR of approximately 6.8%. Stakeholders - including pharmaceutical firms, movement-disorder specialists, neurology and psychiatry clinics, and care providers - have a significant opportunity to address this underserved niche. Those able to deliver effective, accessible, and affordable therapies will play a critical role in shaping the future of TD management worldwide.
This report is also available in the following languages : Japanese (遅発性ジスキネジア市場), Korean (타디브 디스키네시아 시장), Chinese (迟发性运动障碍市场), French (Marché de la dyskinésie tardive), German (Markt für Spätdyskinesie), and Italian (Mercato della discinesia tardiva), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/72077
Our More Reports:
Epilepsy Patient Pool Analysis, Market
https://exactitudeconsultancy.com/reports/72101/epilepsy-patient-pool-analysis-market
Acute Ischemic Stroke (AIS) Market
https://exactitudeconsultancy.com/reports/72103/acute-ischemic-stroke-ais-market
Brain Implants - Global Market
https://exactitudeconsultancy.com/reports/72105/brain-implants-global-market
Cerebrospinal Fluid Management Market
https://exactitudeconsultancy.com/reports/72107/cerebrospinal-fluid-management-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Tardive Dyskinesia (TD) Market Poised for Growth Amid Rising Treatment Adoption and Awareness here
News-ID: 4304113 • Views: …
More Releases from Exactitude Consultancy
Spinal Muscular Atrophy (SMA) Market Set to Grow Strongly Through 2034
The global Spinal Muscular Atrophy (SMA) market is entering a major growth phase, fueled by increased disease awareness, wider access to innovative therapies, and expanding newborn screening programs. With advances in treatment and supportive care, the SMA market is poised for robust expansion over the next decade.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/72075
1. Keyword Definition - Spinal Muscular Atrophy (SMA)
Spinal Muscular Atrophy (SMA) is a genetic neuromuscular disorder…
Small-Fiber Neuropathy (SFN) Market Poised for Rapid Growth as Demand for Neurop …
The global Small-Fiber Neuropathy (SFN) market is witnessing robust growth, driven by rising diabetic and idiopathic neuropathy prevalence, improved diagnostics, and growing demand for effective therapies. The market is expected to show steady long-term expansion through 2034, signaling strong opportunities for healthcare providers, pharma companies, and investors.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/72073
1. Keyword Definition - Small-Fiber Neuropathy (SFN)
Small-Fiber Neuropathy (SFN) is a neurological disorder caused by damage…
Primary Progressive Multiple Sclerosis (PPMS) Market Set for Strong Expansion Th …
The global Primary Progressive Multiple Sclerosis (PPMS) market is entering a new growth phase as disease-modifying therapies gain wider adoption and unmet treatment needs continue to rise. With innovation accelerating and diagnosis rates improving, the PPMS market is projected to show stable long-term expansion through 2034.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/72071
1. Keyword Definition - Primary Progressive Multiple Sclerosis (PPMS)
Primary Progressive Multiple Sclerosis (PPMS) is a rare and…
Pediatric Vaccines Market to Reach USD 84.6 Billion by 2034
Pune, India - December 2025 - The global Pediatric Vaccines Market, valued at USD 46.8 billion in 2024, is projected to reach USD 84.6 billion by 2034, growing at a 6.1% CAGR (2025-2034), according to Exactitude Consultancy. Increasing childhood immunization programs, rising birth rates in emerging economies, and continuous advancements in vaccine development are fueling robust market growth.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/52011
Market Summary
The Pediatric Vaccines…
More Releases for Tardive
Tardive Dyskinesia Treatment Market Analysis By Drug Class & Distribution Channe …
The Tardive Dyskinesia Treatment Market is expected to Reach a CAGR of 4% during the forecast period (2024-2031).
Tardive Dyskinesia Treatment Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it…
Tardive Dyskinesia Market Report and Forecast 2024-2032
The tardive dyskinesia market size is anticipated to grow at a CAGR of 3.2 % during the forecast period of 2024-2032, driven by growing awareness about the importance of monitoring patients on long-term antipsychotic therapy for early signs of tardive dyskinesia in the major markets.
Tardive Dyskinesia: Introduction
Tardive dyskinesia is a neurological disorder characterized by involuntary, repetitive body movements. It primarily affects the face, causing grimacing, blinking, or lip-smacking, but can…
Global Tardive Dyskinesia (TD) Treatment Market - Opportunities & Forecasts, 202 …
Dhirtek Business Research and Consulting recently released its most comprehensive research report to date on the global tardive dyskinesia (td) treatment market. Through extensive research, analysts have provided an extensive look into the market's drivers and restraints, and identified the key milestones and trends that will shape its future.
Primary and secondary research methods were used to create this in-depth report. Through the analysis of the research, Dhirtek was able to…
Tardive Dyskinesia Drugs Market Competitor Landscape, Opportunity Analysis, Grow …
Tardive neurological disorder (TD) may be a kind of dyskinesia that's tough to treat. it's a nerve disorder characterised by involuntary movements like jaw, lips, and tongue, thought-about as grimacing, protrusive the tongue out, and lip smack. another symptoms square measure a private experiencing involuntary movement of the lower and higher extremities and additionally respiratory choking.
Get HOLISTIC Request Sample Copy:https://www.coherentmarketinsights.com/insight/request-sample/218
consistent with Center for Drug analysis and analysis, dyskinesia will…
Antioxidants May Aid in the Treatment of Tardive Dyskinesia
Memphis, TN (May 9, 2019) – Today, The Primary Care Companion for CNS Disorders published a case report on the use of antioxidants in the treatment of tardive dyskinesia. While new pharmacologic discoveries have occurred in the area of movement disorders, their use comes with a large price tag. Thus, for mild cases, clinicians may want to seek out more cost-effective options. Antioxidants may serve a role in the prevention…
Tardive Dyskinesia Market (TD) Developing CAGR During the Forecast 2018-2025
Global Tardive Dyskinesia Market Size, Status and Forecast 2018-2025 market research report, has been prepared based on a deep market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this Global market.
Download PDF Brochure of Tardive Dyskinesia Market spread across 97 Pages, Profiling Companies and Supported with…
